Arvinas, Inc. (ARVN)

Market Cap	1.27B
Revenue (ttm)	161.10M
Net Income (ttm)	-308.60M
Shares Out	68.71M
EPS (ttm)	-4.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,298,449
Open	17.62
Previous Close	17.83
Day's Range	17.55 - 18.70
52-Week Range	17.37 - 53.08
Beta	1.83
Analysts	Strong Buy
Price Target	63.00 (+240.91%)
Earnings Date	Oct 30, 2024

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 445
• Stock Exchange: NASDAQ
• Ticker Symbol: ARVN
• Website: https://www.arvinas.com

Financial Performance

In 2023, Arvinas's revenue was $78.50 million, a decrease of -40.26% compared to the previous year's $131.40 million. Losses were -$367.30 million, 30.0% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for ARVN stock is "Strong Buy." The 12-month stock price forecast is $63.0, which is an increase of 240.91% from the latest price.

Price Target

$63.0

(240.91% upside)

Analyst Consensus: Strong Buy